A clinical trial involving teriparatide has updated its status as of September 3, 2026. The study, titled "Novel Combination Therapy for Osteoporosis in Men," is registered as NCT03994172. It is listed as a Phase 4 trial, indicating research conducted after regulatory approval of the compound. The trial's status has been recorded as completed. No results or outcome data are included in this update. The trial record does not specify findings related to safety or effectiveness at this time. Teriparatide remains an approved compound, and this update reflects only the change in trial status, not new clinical conclusions. Readers interested in additional detail about the study design or its eventual outcomes may consult the official trial registry listing. For more background on teriparatide, including its approved uses and general profile, readers can refer to the compound overview.
Teriparatide Trial "Novel Combination Therapy for Osteoporosis in Men" Completed
See the full teriparatide overview
Source: https://clinicaltrials.gov/study/NCT03994172